{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Facteur X : Questions médicales les plus fréquentes",
"headline": "Facteur X : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Facteur X : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-18",
"dateModified": "2025-04-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Facteur X"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Facteurs de la coagulation sanguine",
"url": "https://questionsmedicales.fr/mesh/D001779",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de la coagulation sanguine",
"code": {
"@type": "MedicalCode",
"code": "D001779",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.119"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Facteur Xa",
"alternateName": "Factor Xa",
"url": "https://questionsmedicales.fr/mesh/D015951",
"about": {
"@type": "MedicalCondition",
"name": "Facteur Xa",
"code": {
"@type": "MedicalCode",
"code": "D015951",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.119.400.315"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Facteur X",
"alternateName": "Factor X",
"code": {
"@type": "MedicalCode",
"code": "D005170",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kaan Kavakli",
"url": "https://questionsmedicales.fr/author/Kaan%20Kavakli",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Division of Hemato-Oncology, Ege University Faculty of Medicine, İzmir, Turkey."
}
},
{
"@type": "Person",
"name": "Glaivy Batsuli",
"url": "https://questionsmedicales.fr/author/Glaivy%20Batsuli",
"affiliation": {
"@type": "Organization",
"name": "Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, Georgia, USA."
}
},
{
"@type": "Person",
"name": "Michael Piper",
"url": "https://questionsmedicales.fr/author/Michael%20Piper",
"affiliation": {
"@type": "Organization",
"name": "School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia. Electronic address: m.piper@uq.edu.au."
}
},
{
"@type": "Person",
"name": "Catherine E McGuinn",
"url": "https://questionsmedicales.fr/author/Catherine%20E%20McGuinn",
"affiliation": {
"@type": "Organization",
"name": "Division of Pediatric Hematology and Oncology, Weill Cornell Medicine, New York, New York, USA."
}
},
{
"@type": "Person",
"name": "Amalie Carnbring Bonde",
"url": "https://questionsmedicales.fr/author/Amalie%20Carnbring%20Bonde",
"affiliation": {
"@type": "Organization",
"name": "Research & Early Development, Novo Nordisk A/S, Måløv, Denmark."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "MGACA-Net: a novel deep learning based multi-scale guided attention and context aggregation for localization of knee anterior cruciate ligament tears region in MRI images.",
"datePublished": "2023-07-13",
"url": "https://questionsmedicales.fr/article/37547408",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7717/peerj-cs.1483"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative evaluations of shear bond strength of mineral trioxide aggregate, Biodentine, and calcium-enriched mixture to bulk-fill flowable composite using three different adhesive systems: An",
"datePublished": "2024-07-08",
"url": "https://questionsmedicales.fr/article/39262590",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4103/JCDE.JCDE_192_24"
}
},
{
"@type": "ScholarlyArticle",
"name": "Long-term outcomes of anatomical and extra-anatomical bypass for the treatment of unilateral iliac artery lesions a systematic review aggregated data and individual participant data meta-analysis.",
"datePublished": "2024-04-06",
"url": "https://questionsmedicales.fr/article/38588957",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.avsg.2024.02.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "Palladium Catalyzed, Annulative Multiple C-H Bond Activations of BODIPYs to Access π-Extended Polycyclic Heteroaromatic Molecules with Deep Red Emissions and Self-aggregation Behaviors.",
"datePublished": "2023-05-05",
"url": "https://questionsmedicales.fr/article/37070968",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/chem.202300449"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immature permanent incisors with complicated crown fractures treated with partial pulpotomy using white mineral trioxide aggregate and IRoot BP plus-a retrospective long-term study.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36409268",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/edt.12804"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Facteurs de la coagulation sanguine",
"item": "https://questionsmedicales.fr/mesh/D001779"
},
{
"@type": "ListItem",
"position": 4,
"name": "Facteur X",
"item": "https://questionsmedicales.fr/mesh/D005170"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Facteur X - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Facteur X",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Facteur X",
"description": "Comment diagnostiquer une déficience en facteur X ?\nQuels tests sont utilisés pour évaluer le facteur X ?\nQuels symptômes indiquent un problème de facteur X ?\nLe facteur X peut-il être mesuré directement ?\nQuelle est l'importance du facteur X dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D005170?mesh_terms=Platelet+Aggregation&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Facteur X",
"description": "Quels sont les symptômes d'une déficience en facteur X ?\nLes saignements de nez sont-ils liés au facteur X ?\nComment se manifestent les saignements internes ?\nLes douleurs articulaires sont-elles un symptôme ?\nLes femmes enceintes peuvent-elles avoir des symptômes liés au facteur X ?",
"url": "https://questionsmedicales.fr/mesh/D005170?mesh_terms=Platelet+Aggregation&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Facteur X",
"description": "Comment prévenir les complications liées au facteur X ?\nLes activités physiques sont-elles sûres ?\nFaut-il éviter certains médicaments ?\nComment éduquer les proches sur le facteur X ?\nLes vaccinations sont-elles sûres pour les patients ?",
"url": "https://questionsmedicales.fr/mesh/D005170?mesh_terms=Platelet+Aggregation&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Facteur X",
"description": "Quel traitement existe pour la déficience en facteur X ?\nLes médicaments anticoagulants affectent-ils le facteur X ?\nComment gérer les saignements liés au facteur X ?\nY a-t-il des traitements préventifs pour le facteur X ?\nLes thérapies géniques sont-elles une option ?",
"url": "https://questionsmedicales.fr/mesh/D005170?mesh_terms=Platelet+Aggregation&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Facteur X",
"description": "Quelles sont les complications possibles du facteur X ?\nLes hémorragies peuvent-elles être mortelles ?\nComment les complications sont-elles gérées ?\nLes complications peuvent-elles affecter la qualité de vie ?\nY a-t-il des risques de complications après un traitement ?",
"url": "https://questionsmedicales.fr/mesh/D005170?mesh_terms=Platelet+Aggregation&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Facteur X",
"description": "Quels sont les facteurs de risque pour une déficience en facteur X ?\nLes femmes sont-elles plus à risque ?\nLes personnes âgées sont-elles plus à risque ?\nLes maladies auto-immunes augmentent-elles le risque ?\nLes interventions chirurgicales augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D005170?mesh_terms=Platelet+Aggregation&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en facteur X ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un test de coagulation spécifique, comme le temps de prothrombine, peut révéler une déficience."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer le facteur X ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de temps de prothrombine et d'activated partial thromboplastin time sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème de facteur X ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements excessifs, des ecchymoses fréquentes et des saignements prolongés peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Le facteur X peut-il être mesuré directement ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests spécifiques peuvent mesurer directement l'activité du facteur X dans le sang."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du facteur X dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial pour évaluer les troubles de la coagulation et orienter le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une déficience en facteur X ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des saignements anormaux, des ecchymoses et des douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Les saignements de nez sont-ils liés au facteur X ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des saignements de nez fréquents peuvent être un signe de déficience en facteur X."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les saignements internes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par des douleurs abdominales, des selles noires ou des vomissements sanglants."
}
},
{
"@type": "Question",
"name": "Les douleurs articulaires sont-elles un symptôme ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs articulaires peuvent survenir en raison de saignements dans les articulations."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes peuvent-elles avoir des symptômes liés au facteur X ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes enceintes peuvent présenter des symptômes de troubles de la coagulation liés au facteur X."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées au facteur X ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut un suivi médical régulier et l'éducation sur les signes de saignement."
}
},
{
"@type": "Question",
"name": "Les activités physiques sont-elles sûres ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des activités à faible impact sont recommandées pour éviter les blessures et les saignements."
}
},
{
"@type": "Question",
"name": "Faut-il éviter certains médicaments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est important d'éviter les médicaments qui augmentent le risque de saignement."
}
},
{
"@type": "Question",
"name": "Comment éduquer les proches sur le facteur X ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Informer les proches sur les symptômes et les soins d'urgence est essentiel pour la prévention."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles sûres pour les patients ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations sont généralement sûres, mais un avis médical est recommandé."
}
},
{
"@type": "Question",
"name": "Quel traitement existe pour la déficience en facteur X ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut inclure des concentrés de facteur X ou des transfusions de plasma frais."
}
},
{
"@type": "Question",
"name": "Les médicaments anticoagulants affectent-ils le facteur X ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains anticoagulants ciblent le facteur X pour prévenir la formation de caillots."
}
},
{
"@type": "Question",
"name": "Comment gérer les saignements liés au facteur X ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'administration de facteur X et le contrôle des saignements par des soins médicaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements préventifs pour le facteur X ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements préventifs peuvent être administrés avant des interventions chirurgicales."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques sont-elles une option ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques pour traiter les déficiences en facteur X."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du facteur X ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des hémorragies graves, des douleurs articulaires et des infections."
}
},
{
"@type": "Question",
"name": "Les hémorragies peuvent-elles être mortelles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des hémorragies internes non traitées peuvent être potentiellement mortelles."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une intervention médicale rapide et un traitement approprié."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles affecter la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications liées au facteur X peuvent significativement affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de complications après un traitement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des risques de complications peuvent persister même après un traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour une déficience en facteur X ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque incluent des antécédents familiaux, des maladies héréditaires et certains médicaments."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la déficience en facteur X affecte les hommes et les femmes de manière égale."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir un risque accru de troubles de la coagulation."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque de déficience en facteur X."
}
},
{
"@type": "Question",
"name": "Les interventions chirurgicales augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interventions chirurgicales peuvent augmenter le risque de saignements liés au facteur X."
}
}
]
}
]
}
Anterior cruciate ligament (ACL) tears are a common knee injury that can have serious consequences and require medical intervention. Magnetic resonance imaging (MRI) is the preferred method for ACL te...
The objective of the study was to assess the shear bond strength of bulk-fill flowable composite resin smart dentin replacement plus when bonded to mineral trioxide aggregate (MTA)-angelus, biodentine...
One hundred and twenty-six cylindrical acrylic blocks used in the study were sorted into three groups based on the bioactive substance used to fill the 3-mm diameter and 3-mm high hole in the center o...
The study showed that the type of adhesive system and the time of bonding affected the shear bond strength of bulk-fill composite to the pulp capping agents (...
MTA demonstrated the highest bond strength with two-step SE group at 15 min, and CEM exhibited the highest bond strength with two-step SE groups at 72 h interval. For biodentine group, the type of adh...
We investigated the long-term safety and efficacy of anatomical and extra-anatomical bypass for the treatment of unilateral iliac artery disease....
A systematic search on PubMed, Scopus and Web of science for articles published by June 2023 was performed. We implemented a two-stage individual participant data (IPD) meta-analysis and pooled surviv...
Ten studies encompassing 1907 patients were included. The five- and ten-year pooled primary patency for anatomical bypass was 83.27% (95% CI:69.99- 99.07) and 77.30% (95% CI:60.32- 99.04), with a mean...
While we have demonstrated favorable long-term primary and secondary patency outcomes for both surgical techniques, anatomical bypass exhibited a reduced risk of primary patency loss potentially refle...
Aromatic ring fusion on BODIPY core can effectively tune its electronic property, and red-shift its absorption and emission wavelength. In this work, we report that a one-pot Pd(II) catalyzed multiple...
Calcium silicate cements have been widely used for pulpotomies in immature permanent teeth with complicated crown fractures due to their superior properties. However, few studies have evaluated the lo...
Children who had partial pulpotomies of immature permanent incisors with complicated crown fractures using WMTA or iRoot BP Plus as capping agents were enrolled. Eighty immature permanent incisors in ...
The clinical and radiographic success rates in the WMTA (n = 36) and iRoot BP Plus groups (n = 44) were 94.4% versus 97.7% and 88.9% versus 97.7%, respectively (both p < .05). The average observation ...
Both WMTA and iRoot BP Plus had favorable outcomes in promoting physiological development and maintaining the basic functions of immature permanent incisors with complicated crown fractures. As a part...
Overall response rate (ORR) and progression-free survival (PFS) are commonly used as endpoints for phase II trials. However, the ultimate goal is to bring survival benefit for the patients. We aimed t...
Clinical trials were identified using Medline database. Studies only enrolling patients with gallbladder cancer were not included. Searches were last updated on April 2020. Eligible studies reported O...
Seventeen studies (N = 912 patients) were selected. There was a strong correlation between median OS/ORR in the overall analysis (r = 0.85; P < 0.0001), both for trials with chemotherapy (r = 0.90; P=...
ORR seems to be a more interesting intermediate endpoint in BTC in second line for both chemotherapy and targeted therapies, while PFS may be relevant only for targeted therapy trials. Further well-de...
To study the ultra-trace simultaneous determination of drugs, the colorimetric method in combination with chemometrics can be used....
In this study, a simple, rapid, and sensitive UV-Vis spectrophotometric method using gold nanoparticles (AuNPs) was introduced for the simultaneous determination of ultra-trace amounts of Pilocarpine ...
AuNPs interacted with components and the aggregation mode of NPs occurred and finally, the color change of the solution (red to gray) was observed with the naked eye without the most modern and expens...
The validation of the colorimetric way was studied in the concentration range of 100-800 and 100-600 μg/L with good linearity equal to 0.9772 and 0.9891 for PIL and TIM, respectively. The limit of det...
The colorimetric method can be introduced as a proper option for the simultaneous determination of components in pharmaceutical formulations and other samples....
A colorimetric method using AuNPs was proposed.PLS method was coupled with a colorimetric method for the ultra-trace simultaneous estimation of PIL and TIM in binary mixtures.Ultra-trace amounts of PI...
The tendency of polypeptide chains to deviate from their conventional protein folding pathway and instead get trapped as off-pathway intermediates, has been a matter of great concern. These off-pathwa...
We report the results of glucose measurements performed during one year by the same measurement procedures (MPs) in 58 Norwegian hospital laboratories using control materials provided by external qual...
Data from six Labquality and three Noklus glucose EQA surveys were aggregated for each MP (Abbott Alinity, Abbott Architect, Roche Cobas, and Siemens Advia) in each scheme. For each EQA result, percen...
The median % biases observed for each MP in the Labquality scheme were significantly larger than those in the Noklus scheme, which uses verified commutable control materials and highest-order referenc...
This study underlines the importance of using verified commutable EQA materials and target values traceable to reference MPs in EQA schemes designed for assessment of metrological traceability of labo...